IVERMECTIN - COVID "MIRACLE DRUG": Dr. Pierre Kory testifies 12/8/20 before Senate Committee on Homeland Security and Governmental Affairs

 “It will all be needless death from here on out, given that there is a readily available scientific solution to the pandemic," --Dr. Pierre Kory (president, FLCCC Alliance) 12/8/2020

Newswise — WASHINGTON, D.C. — DECEMBER 8, 2020: Appearing as a witness Tuesday morning before the Senate Committee on Homeland Security and Governmental Affairs – which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution” – Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin.

The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.

Dr. Kory testified that Ivermectin is effectively a “miracle drug” against COVID-19 and called upon the government’s medical authorities – the NIH, CDC, and FDA – to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to prescribe Ivermectin for Covid-19.

“People are dying at unacceptable and untold rates,” Dr. Kory told the Senate panel. “I am a lung and ICU specialist, and all I do right now is take care of COVID-19 patients dying of breathlessness in ICUs. By the time they get to the ICU, it is nearly impossible to save most patients. They simply cannot breathe.”

READ MORE:

https://www.newswise.com/coronavirus/dr-pierre-kory-president-of-the-flccc-alliance-testifies-before-senate-committee-on-homeland-security-and-governmental-affairs-looking-into-early-outpatient-covid-19-treatment

https://www.newswise.com/coronavirus/dr-pierre-kory-president-of-the-flccc-alliance-testifies-before-senate-committee-on-homeland-security-and-governmental-affairs-looking-into-early-outpatient-covid-19-treatment